- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06406114
세팔로스포린 알레르기 검사에 대한 진단 접근법 최적화 (DACAT)
Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.
연구 개요
상태
개입 / 치료
- 의약품: Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing
- 의약품: Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge
- 의약품: Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge
- 의약품: Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge
- 의약품: Amoxicillin double-blind placebo-controlled drug challenge
상세 설명
Background:
In the United States, beta-lactam antibiotics are the leading cause of allergic reactions. Cephalosporin antibiotics, in particular, are the most common cause of drug-induced anaphylaxis and perioperative allergy. For penicillin allergy, the mechanism of allergy and the antigenic determinants are known; validated penicillin skin testing followed by drug challenge has a 100% negative predictive value to exclude an immunoglobulin (Ig)E-mediated reaction. For cephalosporin allergy, the antigenic determinants and mechanism are not known, and skin testing is not validated. The diagnostic test characteristics of skin testing with native cephalosporins remain unclear with no sensitivity nor specificity reported. Although beta-lactam cross-reactivity has been hypothesized to be from the similarity of the R1 side chains, rather than the beta-lactam ring, cross-reactivity estimates among beta-lactams vary. Furthermore, it is not known whether the variance in cross-reactivity is due to true allergy versus sensitization based on positive skin testing, given that drug challenges were not performed on skin-test-positive patients. While an IgE mechanism is assumed for cephalosporin allergy and supported by skin testing that has been positive, the biology has yet to be characterized, and some cephalosporin anaphylaxis can occur on the first exposure, which is inconsistent with an IgE mechanism. Given the complexity of cephalosporin structures and potential epitopes, there may be several distinct biologic pathways involved in cephalosporin allergy. Future diagnostics in cephalosporin allergy are reliant on determination of these biological pathways and finding key haptens.
Aims:
Current national practice guidelines related to cephalosporin allergy assessment are conditional and based on low-quality evidence. The overall goal is to identify the optimal diagnostic approach to cephalosporin allergy and determine beta-lactam cross-reactivity, while discovering the mechanism and antigenic determinants of cephalosporin allergy to advance future diagnostics. The investigators will do this through a clinical trial that will generate empirical evidence through novel trial procedures, double-blind skin testing, and double-blind placebo-controlled drug challenges. Specific aims are: 1) To determine the optimal approach to cephalosporin allergy evaluation; 2) To assess beta-lactam cross-reactivity in cephalosporin-allergic individuals; and 3) To investigate the antigenic determinants and mechanism of cephalosporin allergy.
Study Overview:
Enrolled and consented subjects will attend Visit 1 for baseline screening, sample collection, double-blind skin testing to a beta-lactam panel, and a double-blind placebo-controlled challenge to their culprit cephalosporin antibiotic. Results of the culprit cephalosporin challenge determine subject's study timeline. Subjects confirmed as non-allergic to their culprit cephalosporin will return for the End-of-Study Visit for venipuncture and blood collection, ending their participation in the study. Subjects who are confirmed as allergic to their culprit at Visit 1 will return for three additional visits; Visits 2 and 3 will include double-blind placebo-controlled challenges to a similar side chain and dissimilar side chain cephalosporin (as compared to the side chain of their culprit) to assess cross-reactivity. The order of these two challenges is randomized between Visit 2 and 3, and the order of whether a similar or dissimilar side chain cephalosporin is challenged first (in Visit 2) differentiates the comparator arms of this study. In Visit 4, subjects from both comparator arms will undergo a double-blind placebo-controlled challenge to a penicillin to assess cross-reactivity between cephalosporins and penicillins. After completion of this penicillin challenge, confirmed-allergic participants will return for an End-of-Study Visit. This visit will mark the end of their participation in the study. Venipuncture and sample collection will occur at each visit.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Kell Lopez, BS
- 전화번호: 6177320589
- 이메일: klopez5@bwh.harvard.edu
연구 연락처 백업
- 이름: Cara Yelverton, BSc, PhD
- 전화번호: 6177242415
- 이메일: cyelverton@mgh.harvard.edu
연구 장소
-
-
Arizona
-
Scottsdale, Arizona, 미국, 14607
- 모병
- Mayo Clinic Arizona
-
연락하다:
- Alexei Gonzalez-Estrada, MD
- 전화번호: 904-953-2451
- 이메일: gonzalez.alexei@mayo.edu
-
연락하다:
- Renee Nunez, BS
- 전화번호: 480-574-1826
- 이메일: Nunez.Renee@mayo.edu
-
수석 연구원:
- Alexei Gonzalez-Estrada, MD
-
-
California
-
San Francisco, California, 미국, 94143
- 모병
- University of California, San Francisco
-
연락하다:
- Monica Tang, MD
- 전화번호: 415-514-8044
- 이메일: dacat@ucsf.edu
-
연락하다:
- Jade Vi
- 전화번호: 415-476-1783
- 이메일: dacat@usf.edu
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- 모병
- Massachusetts General Hospital
-
연락하다:
- Aleena Banerji, MD
- 전화번호: 6177263850
- 이메일: ABANERJI@mgh.harvard.edu
-
수석 연구원:
- Aleena Banerji, MD
-
연락하다:
- Noah Im, BS
- 전화번호: 617-726-2974
- 이메일: noim@mgh.harvard.edu
-
-
New York
-
Rochester, New York, 미국, 14621
- 모병
- Rochester General Hospital
-
연락하다:
- Allison C Ramsey, MD
- 전화번호: 585-922-8350
- 이메일: allison.ramsey@rochesterregional.org
-
연락하다:
- Dawn Shefflin, RN
- 전화번호: 585-922-8314
- 이메일: dawn.sheflin@rochesterregional.org
-
수석 연구원:
- Allison C Ramsay, MD
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37232
- 모병
- Vanderbilt University Medical Center
-
연락하다:
- Elizabeth Phillips, MD
- 전화번호: 6153100339
- 이메일: elizabeth.j.phillips@vumc.org
-
수석 연구원:
- Elizabeth Phillips, MD
-
연락하다:
- April O'Connor, RN
- 전화번호: 615-957-6057
- 이메일: april.oconnor@vumc.org
-
-
Texas
-
Dallas, Texas, 미국, 75390
- 모병
- University of Texas Southwestern Medical Center
-
연락하다:
- David A Khan, MD
- 전화번호: 214-406-5119
- 이메일: Dave.Khan@UTSouthwestern.edu
-
수석 연구원:
- Dave Khan, MD
-
연락하다:
- Sophia Lopez, BS
- 전화번호: 469-444-0531
- 이메일: Sophia.Lopez@UTSouthwestern.edu
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age 18-70 years old.
- Reaction history consistent with a potential immediate hypersensitivity reaction (pruritus, urticaria, erythema, angioedema, bronchospasm, wheezing, shortness of breath, anaphylaxis, or hypotension) to cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime.
- English speaking or non-English speaking with translation services available.
Exclusion Criteria:
- Severe concomitant medical condition (e.g., unstable coronary artery disease, congestive heart failure, severe chronic obstructive pulmonary disease, poorly controlled asthma, chronic renal failure, cirrhosis, or end-stage liver disease.)
- History of Clostridioides difficile infection
- Chronic spontaneous urticaria or systemic mastocytosis
- Incident reaction required cardiopulmonary resuscitation
- Reaction to 2 or more cephalosporin antibiotics
- Active infection or antibiotic treatment within 7 days
- Treatment with systemic antihistamines or corticosteroids within 7 days
- Treatment with omalizumab or dupilumab within 60 days
- Significant immunosuppression
- Treatment with a beta-blocker or ACE inhibitor within 7 days
- Use of investigational drugs within 60 days of participation
- Anaphylaxis in the last 30 days
- Penicillin anaphylaxis within the past year confirmed with positive penicillin skin tests
- Prison or jail inmates, pregnant women, severe cognitive impairment
- Current, diagnosed, mental illness or current, diagnosed, or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements
- Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
- Inability or unwillingness of a participant to give written informed consent or comply with study protocol
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Similar cephalosporin first
In visit 2, confirmed-allergic subjects will have a double-blind placebo-controlled drug challenge to a similar side chain cephalosporin, followed by a double-blind placebo-controlled challenge to a dissimilar side chain cephalosporin in visit 3. The randomization of which cephalosporin (similar or dissimilar side chain) is challenged in visits 2 and 3 differentiates the two arms. |
Percutaneous and intradermal skin testing will be performed in all participants. Concentrations for percutaneous testing; cefazolin (330 mg/ml), cefuroxime (90 mg/ml), ceftazidime (100 mg/ml), ceftriaxone (100 mg/ml), cefepime (200 mg/ml), pre-pen (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (6 mg/ml). Concentrations for the first intradermal testing; cefazolin (3.3mg/ml), cefuroxime (1 mg/ml), ceftazidime (1 mg/ml), ceftriaxone (1 mg/ml), cefepime (2 mg/ml), Pre-PEN (undiluted), penicillin G (1000 U/ml), ampicillin (20 mg/ml), and histamine (0.1 mg/ml). Concentrations for the second intradermal testing; cefazolin (33mg/ml), cefuroxime (10 mg/ml), ceftazidime (10 mg/ml), ceftriaxone (10 mg/ml), cefepime (20 mg/ml), Pre-PEN (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (0.1 mg/ml). Histamine and saline will be used as positive and negative controls. After double-blind skin testing, participants will undergo a 3-step double-blind placebo-controlled drug challenge to their culprit cephalosporin (the cephalosporin they are suspected to be allergic to, either cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime). The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that shares a similar side chain with their culprit. This will be cefepime for those allergic to ceftriaxone, cefaclor for those allergic to cephalexin, cefixime for those allergic to cefdinir, cefdinir for those allergic to cefixime, cephalexin for those allergic to cefaclor or cephadroxil, and ceftriaxone for those allergic to cefepime, cefuroxime, or cefpodoxime. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that has a dissimilar side chain to their culprit. This will be ceftriaxone for those allergic to cefazolin, and cefazolin for those allergic to any other cephalosporin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. Participants will optionally undergo a 3-step double-blind placebo-controlled drug challenge to Amoxicillin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. The order of challenge to similar vs. dissimilar cephalosporin will be randomized as well. |
|
실험적: Dissimilar cephalosporin first
In visit 2, confirmed-allergic subjects will have a double-blind placebo-controlled drug challenge to a dissimilar side chain cephalosporin, followed by a double-blind placebo-controlled challenge to a similar side chain cephalosporin in visit 3. The randomization of which cephalosporin (similar or dissimilar side chain) is challenged in visits 2 and 3 differentiates the two arms. |
Percutaneous and intradermal skin testing will be performed in all participants. Concentrations for percutaneous testing; cefazolin (330 mg/ml), cefuroxime (90 mg/ml), ceftazidime (100 mg/ml), ceftriaxone (100 mg/ml), cefepime (200 mg/ml), pre-pen (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (6 mg/ml). Concentrations for the first intradermal testing; cefazolin (3.3mg/ml), cefuroxime (1 mg/ml), ceftazidime (1 mg/ml), ceftriaxone (1 mg/ml), cefepime (2 mg/ml), Pre-PEN (undiluted), penicillin G (1000 U/ml), ampicillin (20 mg/ml), and histamine (0.1 mg/ml). Concentrations for the second intradermal testing; cefazolin (33mg/ml), cefuroxime (10 mg/ml), ceftazidime (10 mg/ml), ceftriaxone (10 mg/ml), cefepime (20 mg/ml), Pre-PEN (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (0.1 mg/ml). Histamine and saline will be used as positive and negative controls. After double-blind skin testing, participants will undergo a 3-step double-blind placebo-controlled drug challenge to their culprit cephalosporin (the cephalosporin they are suspected to be allergic to, either cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime). The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that shares a similar side chain with their culprit. This will be cefepime for those allergic to ceftriaxone, cefaclor for those allergic to cephalexin, cefixime for those allergic to cefdinir, cefdinir for those allergic to cefixime, cephalexin for those allergic to cefaclor or cephadroxil, and ceftriaxone for those allergic to cefepime, cefuroxime, or cefpodoxime. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that has a dissimilar side chain to their culprit. This will be ceftriaxone for those allergic to cefazolin, and cefazolin for those allergic to any other cephalosporin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. Participants will optionally undergo a 3-step double-blind placebo-controlled drug challenge to Amoxicillin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. The order of challenge to similar vs. dissimilar cephalosporin will be randomized as well. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of participants with confirmed culprit cephalosporin allergy
기간: Up to 7 weeks
|
Placebo-controlled drug challenges will be used to confirm or disprove participant's cephalosporin allergies, and the proportion of included participants with confirmed allergies will be measured. |
Up to 7 weeks
|
|
Cephalosporin skin test sensitivity and specificity
기간: Up to 7 weeks
|
Challenge results will be used as a reference standard to determine the sensitivity and specificity of cephalosporin skin testing. |
Up to 7 weeks
|
|
Proportion of cross-reactivity to other cephalosporins in confirmed-allergic subjects
기간: Up to 7 weeks
|
The proportion of participants with confirmed cross-reactivity to dissimilar/similar cephalosporins than their culprit will be determined. |
Up to 7 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Culprit cephalosporin skin test diagnostic characteristics
기간: Up to 7 weeks
|
The diagnostic testing characteristics of culprit cephalosporin skin tests will be evaluated, including positive predictive value (PPV), negative predictive value (NPV), and false positive rate. |
Up to 7 weeks
|
|
Cephalosporin skin test diagnostic characteristic performance differences between risk groups
기간: Up to 7 weeks
|
Allergy history risk will be measured using a validated Drug Allergy History Tool. The PPV, NPV, and false positive rate of skin testing will then be compared through regression modeling to show differences in diagnostic characteristic performance between high-risk and low-risk groups. |
Up to 7 weeks
|
|
Association between patient demographics and confirmed cephalosporin allergy
기간: Up to 7 weeks
|
Participant demographic traits will be collected and their associations with confirmed cephalosporin allergy will be presented as odds ratios with 95% confidence intervals. |
Up to 7 weeks
|
|
Association between patient allergy history and confirmed cephalosporin allergy
기간: Up to 7 weeks
|
A validated Drug Allergy History Tool will be used to collect participant's allergy history, and associations of allergy history with confirmed cephalosporin allergy will be presented as odds ratios with 95% confidence intervals. |
Up to 7 weeks
|
|
Proportion of nocebo responders
기간: Up to 7 weeks
|
The rate of nocebo response in those undergoing cephalosporin drug challenges will be measured. |
Up to 7 weeks
|
|
Cephalosporin-specific antibody levels
기간: Up to 54 months
|
Cephalosporin drug- and hapten-specific antibody levels will be evaluated from serum using ELISA. |
Up to 54 months
|
|
Cephalosporin-specific antibody binding
기간: Up to 54 months
|
Cephalosporin drug antibody binding epitopes will be presented using nanoallergens to evaluate rates of antibody binding and cell degranulation to gain a mechanistic understanding of cephalosporin allergy. |
Up to 54 months
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Prevalence of nocebo response
기간: Up to 7 weeks
|
The prevalence of nocebo responses to drug challenges will be measured to understand how often these responses occur during cephalosporin challenges. |
Up to 7 weeks
|
|
Graded severity of nocebo response reactions
기간: Up to 7 weeks
|
Respiratory, mucocutaneous, and cardiovascular symptoms and clinical presentation of nocebo response reactions will be collected and graded using the United States Drug Allergy Registry (USDAR) grading scale to determine the average severity of nocebo reactions. This scale is scored as either NR (no reaction) or values 0-4 indicating the severity of the reaction, with 0 being the mildest and 4 being the most severe. |
Up to 7 weeks
|
|
Cephalosporin skin test clinical statistics
기간: Up to 7 weeks
|
The average diameter size of the wheal and flare during cephalosporin skin tests will be determined. |
Up to 7 weeks
|
|
Tryptase levels in those with confirmed allergy
기간: Up to 7 weeks
|
In participants with confirmed cephalosporin allergy, tryptase levels will be evaluated and compared to determine if tryptase levels are associated with reaction grades. |
Up to 7 weeks
|
|
Amoxicillin cross-reactivity in those with confirmed cephalosporin allergy
기간: Up to 7 weeks
|
Among those with confirmed cephalosporin allergy, the proportion with cross-reactivity to amoxicillin will be determined. |
Up to 7 weeks
|
|
Amoxicillin skin test diagnostic characteristics in those with confirmed cephalosporin allergy
기간: Up to 7 weeks
|
Among those with confirmed cephalosporin allergy, the skin test diagnostic characteristics with amoxicillin will be determined, including positive predictive value (PPV), negative predictive value (NPV), and false positive rate. |
Up to 7 weeks
|
|
Similar cephalosporin skin test diagnostic characteristics in participants with confirmed cephalosporin allergy
기간: Up to 7 weeks
|
Among those with confirmed cephalosporin allergy, the skin test diagnostic characteristics with a similar side-chain cephalosporin will be determined, including positive predictive value (PPV), negative predictive value (NPV), and false positive rate. |
Up to 7 weeks
|
|
Dissimilar cephalosporin skin test diagnostic characteristics in participants with confirmed cephalosporin allergy
기간: Up to 7 weeks
|
Among those with confirmed cephalosporin allergy, the skin test diagnostic characteristics with a dissimilar side-chain cephalosporin will be determined, including positive predictive value (PPV), negative predictive value (NPV), and false positive rate. |
Up to 7 weeks
|
|
Graded severity of cephalosporin allergic reactions
기간: Up to 7 weeks
|
Respiratory, mucocutaneous, and cardiovascular symptoms and clinical presentation of cephalosporin allergic reactions will be collected and graded using the United States Drug Allergy Registry (USDAR) grading scale to determine the average severity of cephalosporin reactions. This scale is scored as either NR (no reaction) or values 0-4 indicating the severity of the reaction, with 0 being the mildest and 4 being the most severe. |
Up to 7 weeks
|
|
Proportion of delayed hypersensitivity reactions to cephalosporins
기간: Up to 7 weeks
|
The proportion of participants with delayed hypersensitivity reactions to cephalosporins will be recorded. |
Up to 7 weeks
|
|
Incidence of adverse events with cephalosporin diagnostic tests
기간: Up to 7 weeks
|
The incidence rate of allergic and nonallergic adverse events (as graded by the United States Drug Allergy Registry (USDAR) grading scale [grades NR for no reaction and then grades 0-4 with four being the most severe reaction] and National Cancer Institute's Common Terminology Criteria for Adverse Events [grades 1 to 5, with grades 1 being the mildest and grade 5 being death]) in cephalosporin skin tests and drug challenges will be determined. |
Up to 7 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: David A Khan, MD, University of Texas Southwestern Medical Center
- 수석 연구원: Kimberly G Blumenthal, MD, MSc, Mayo Clinic
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 면역계 질환
- 과민성, 즉시
- 화학적으로 유발된 장애
- 약물 관련 부작용 및 부작용
- 과민증
- 아나필락시스
- 약물 과민증
- 황 화합물
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- Azoles
- 생물학적 요인
- 이미 다졸
- 아미드
- 아민
- 에틸 아민
- 베타-락탐
- 락탐
- 세 팔로 스포린
- 티아 지인
- 세 팔로 리딘
- Autacoids
- 염증 매개체
- 생체 모노 아민
- 생체 아민
- 페니실린
- Cephacetrile
- 세프디니르
- 세페핌
- 세프포독심
- 세프트리악손
- 세파졸린
- 세팔렉신
- 암피실린
- 세프타지딤
- 세푸록심
- 세포탁심
- 세픽심
- 페니실린 G
- 세파드록실
- 세파클로르
- 히스타민
- 모노박탐
- 벤질페니실로일 G 폴리리신
기타 연구 ID 번호
- 2024p000928
- U01AI184071 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Data will include demographics, clinical and procedure outcomes, and laboratory results. Investigators will preserve and share de-identified individual participant-level data (IPD) through submission to a controlled-access public repository. Investigators will apply the Safe Harbor method for de-identification of participant data. Participant informed consent forms will reflect this plan. To facilitate the use and interpretation of these data, the study protocol, data collection forms, case report forms, data dictionary, manual of operations, statistical analysis plan, and source code will be shared. Investigators will use Persistent Unique Identifiers (PIDs) to improve data findability across all dissemination outputs. PIDs used will include ORCID iDs for people, DOIs for outputs (e.g., datasets, protocols), and Research Resource IDentifiers (RRIDs) for resources. Investigators will also use indexed metadata to make scientific data easily findable.
IPD 공유 기간
All scientific data generated from this project will be made available as soon as possible, and no later than the time of publication or the end of the funding period, whichever comes first. The duration of preservation and sharing of the data will be a minimum of 5 years after the funding period.
IPD 공유 액세스 기준
Access to the data will be shared under controlled-access conditions as required by the policies of NIH/NIAID and the Mass General Brigham (MGB), which will serve as the sIRB. In accordance with HIPAA, scientific data derived from humans will be protected through de-identification, removal of information that may be used to infer the identity and shared under controlled-access conditions as required by NIH/NIAID and MGB institutional policy.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- ANALYTIC_CODE
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .